Colorectal Cancer Management
Colorectal cancer is one of the most prevalent cancers in North America. It strikes approximately 165,000 people and causes nearly 60,000 deaths each year in the United States and Canada. With an overall 5-year survival rate of 65%, colorectal cancer is the second leading cause of cancer death, accounting for almost 9% of all cancer deaths.
Colorectal cancer develops slowly as premalignant polyps that occur on the bowel wall and eventually increase in size and become cancerous. Colorectal cancer is curable if caught early enough, and proper staging is important to determine the extent of cancer involvement and if therapy is warranted.
DiagnoCure’s pipeline currently includes two focal areas for colorectal cancer, one involving the marker Guanylyl Cyclase C and the other surrounding Shc proteins. This section of the website takes you through several topics related to the Company’s investments in colorectal cancer:
- Colorectal Cancer FAQ provides information on the disease and the current unmet clinical needs.
- GCC (GUY2C) Marker summaries scientific findings about this biomarker with utility in determining recurrence risk and, in turn, helping physicians and patients make more informed treatment decisions.
- Previstage™ GCC Colorectal Cancer Staging Test shares information on this recently released test, which provides deeper insight into which patients might experience a recurrence of their cancer.
- GCC Monitoring Blood Test previews this under-development product.
- Shc Proteins summarizes work in progress for tests that, in studies to date, have been validated for five tumor types including breast and colon, to help predict risk of recurrence and predict response to certain therapies.
- GCC Scientific Publications lists important peer-reviewed publications covering the utility of GCC.